Purpose: Despite exercise's known benefits for cancer patients, little is understood about combining it with immune checkpoint inhibitors (ICI). This study aims to assess the feasibility and acceptability of a personalized physical activity program for cancer patients on ICI treatment and to investigate its effects on quality of life, ICI-related side effects, fatigue, and emotional symptoms.
Methods: This prospective study was conducted across eight cancer practices in a joint network in Brazil. Eligible cancer patients undergoing ICIs were recruited from June 2022 to January 2023. Participants completed a 12-week physical activity program with remote supervision. Baseline and 12-week assessments utilized the FACT-ICM, BFI, ESAS, PROMIS-Anxiety, and FCR-7 scales. Feasibility and acceptability were evaluated based on enrollment, retention, and adherence rates, with patient feedback collected at week 12. Linear mixed models were employed to assess outcomes.
Results: Out of 38 patients, 81% showed high adherence, 62% engaged in activities more than 4 days weekly, and 97% were satisfied with the program. The sample was mostly female (55%), median age of 60.5, primarily diagnosed with breast cancer (26%) and renal cell carcinoma (24%), with 60.5% having metastatic cancer. Sixty percent received ICI combined with chemotherapy. Significant improvements were observed over time in treatment-related side effects, emotional symptoms, and quality of life (p < 0.001).
Conclusion: These findings endorse integrating an exercise program with remote supervision into the care of cancer patients undergoing ICI treatment. This intervention may positively impact symptom management and quality of life, offering a cost-effective approach in oncologic treatment and survivorship care globally.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00520-024-09056-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Current Strategies and Future Dimensions in the Development of KRAS Inhibitors for Targeted Anticancer Therapy.
Drug Dev Res
February 2025
South University School of Pharmacy, Savannah, Giorgia, USA.
KRAS is a proto-oncogene that is found to be mutated in 15% of all metastatic cancers with high prevalence in pancreatic, lung, and colorectal cancers. Additionally, patients harboring KRAS mutations respond poorly to standard cancer therapy. As a result, KRAS is seen as an attractive target for targeted anticancer therapy.
View Article and Find Full Text PDFA novel MRI-based radiomics for preoperative prediction of lymphovascular invasion in rectal cancer.
Abdom Radiol (NY)
January 2025
Department of Radiology, Taizhou Municipal Hospital, Taizhou, Zhejiang, China.
Background: To develop and validate a clinical-radiomics model for preoperative prediction of lymphovascular invasion (LVI) in rectal cancer.
Methods: This retrospective study included data from 239 patients with pathologically confirmed rectal adenocarcinoma from two centers, all of whom underwent MRI examinations. Cases from the first center (n = 189) were randomly divided into a training set and an internal validation set at a 7:3 ratio, while cases from the second center (n = 50) constituted the external validation set.
Transforming cancer screening: the potential of multi-cancer early detection (MCED) technologies.
Int J Clin Oncol
January 2025
Translational Research Support Section, National Cancer Center Hospital East, Chiba, Japan.
Early cancer detection substantially improves the rate of patient survival; however, conventional screening methods are directed at single anatomical sites and focus primarily on a limited number of cancers, such as gastric, colorectal, lung, breast, and cervical cancer. Additionally, several cancers are inadequately screened, hindering early detection of 45.5% cases.
View Article and Find Full Text PDFThe prognostic value of changes in Ki67 following neoadjuvant chemotherapy in residual triple-negative breast cancer: a Swedish nationwide registry-based study.
Breast Cancer Res Treat
January 2025
Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Article Synopsis
- The study investigates how changes in the Ki67 biomarker before and after neoadjuvant chemotherapy (NACT) affect survival in patients with triple-negative breast cancer (TNBC).
- Among 1,777 TNBC patients analyzed, most showed a decrease in tumor size and Ki67 levels after NACT, though many had no change or experienced treatment discontinuation.
- Patients with unchanged Ki67 had significantly worse overall and disease-specific survival compared to those with decreased Ki67, emphasizing the need for personalized treatment strategies based on ongoing monitoring of this biomarker.
Sex Differences in Melanoma Survival-a GEM study.
JNCI Cancer Spectr
January 2025
University of New Mexico Comprehensive Cancer Center, Division of Epidemiology, Biostatistics and Preventive Medicine, Department of Internal Medicine, School of Medicine, University of New Mexico, Albuquerque, NM, USA.
Sex differences in melanoma are prominent, with females having a significant survival advantage. However, it is unclear why we see this survival advantage. Here we investigate the relationship between sex, clinicopathologic variables, and melanoma specific survival in 1,753 single primary melanomas from patients in the GEM study.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!